Allergan, Inc.Underwriting Agreement • March 12th, 2013 • Allergan Inc • Pharmaceutical preparations • New York
Allergan, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $250,000,000 principal amount of the 1.350% Notes due 2018 of the Company (the “2018 Notes”) and an aggregate of $350,000,000 principal amount of 2.800% Notes due 2023 of the Company (the “2023 Notes” and together with the 2018 Notes, the “Securities”). Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Securities.
ALLERGAN, INC. AND WELLS FARGO BANK, NATIONAL ASSOCIATION, Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of March 12, 2013 $250,000,000 1.350% Notes due 2018 and $350,000,000 2.800% Notes due 2023First Supplemental Indenture • March 12th, 2013 • Allergan Inc • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of March 12, 2013 (this “First Supplemental Indenture”), between Allergan, Inc., a corporation existing under the laws of the State of Delaware, with offices at 2525 Dupont Drive, Irvine, California 92612 (the “Company”), and Wells Fargo Bank, National Association, a national banking association, duly organized and validly existing under the laws of the United States of America, having its corporate trust office at 707 Wilshire Blvd., 17th Floor, Los Angeles, California 90017, Attention: Corporate Trust Department, as trustee (the “Trustee”).
